Contribute Try STAT+ Today

Top executives for genome-editing companies on Monday pushed back against a new unpublished paper that raised concerns about preexisting immune responses to CRISPR-based therapies, insisting the issues outlined in the study were either already being addressed or were not relevant to the medicines being developed.

The paper, which was posted Friday on the preprint site bioRxiv, sent shares of Intellia Therapeutics and Editas Medicine down sharply Monday morning. Shares of CRISPR Therapeutics also declined.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.